675 studies (9 from unattributed sources) on Tirzepatide curated from PubMed, ClinicalTrials.gov, and EuropePMC. Updated daily.
Independent certificate-of-analysis evidence from third-party labs — the data behind the studies. Updated as new COAs are verified. Read the full grey-market analysis →
| Manufacturer | Batches | Avg purity | |
|---|---|---|---|
| Bfflist Amo | 247 | 99.61% | View COA → |
| Sry Labs | 207 | 99.55% | View COA → |
| Shanghai Sigma Audley Ssa | 140 | 99.56% | View COA → |
| Hk Peptides | 133 | 99.76% | View COA → |
| Allen Biotechnology Co Abc | 125 | 99.66% | View COA → |
| Planet Peptide | 105 | 99.76% | View COA → |
| GYC | 96 | 99.73% | View COA → |
| Zlz Peptide | 94 | 99.72% | View COA → |
Recent certificates: #63656 (99.855%) · #63634 (99.689%) · #63743 (99.823%) · #27962 (99.94%) · #28001 (99.52%) · #30760 (99.98%)
Manufacturers with published third-party certificates of analysis for Tirzepatide. Open a vendor to see every batch we've verified.
This trial could fundamentally shift how **tirzepatide** is initiated and escalated for **obesity** management, moving towards a more personalized approach. If successful, a **flexible, symptom-guided titration protoc…
**This study is crucial for understanding Tirzepatide's role in the Japanese Type 2 Diabetes population.** If positive, it could lead to **Tirzepatide** becoming a preferred option for patients seeking superior glycem…
This review highlights a novel synergistic pathway, suggesting that **optimizing gut microbiota composition, specifically `Akkermansia muciniphila` levels, could enhance the efficacy of GLP-1-based therapies** for **T…
This review fundamentally shifts the understanding of **Insulin Resistance (IR)** from a diabetes-centric view to a broader systemic metabolic risk state with direct implications for **cancer prevention**. For clinici…
This meta-analysis provides compelling evidence that **GLP-1 based therapies offer phenotype-specific benefits in heart failure**, particularly for **HFpEF** and younger **HFrEF** patients. For peptide users and clini…
This study provides critical insights for healthcare professionals and patients, indicating that the safety profiles of **semaglutide**, **liraglutide**, and **tirzepatide** may extend beyond their current SmPC descri…
This pharmacovigilance study provides critical real-world data on the psychiatric safety profile of GLP-1 receptor agonists, offering a more nuanced understanding beyond clinical trial settings. **Clinicians should ex…
For individuals undergoing **lumbar fusion** who are also candidates for GLP-1 RA therapy, this study suggests that **tirzepatide** may offer a distinct advantage in reducing long-term mechanical complications. The du…
Tirzepatide-treated early weight responders (≥5% loss by Week 8) showed significantly greater weight reduction and cardiometabolic improvements by Week 72 compared to non-responders, with comparable GI tolerability.
This real-world comparison provides crucial evidence for patients and clinicians navigating treatment options for severe **obesity**. **Bariatric surgery remains the most effective intervention for achieving substanti…
For individuals utilizing GLP-1-based therapies, this review underscores a critical shift from solely focusing on total weight loss to prioritizing **quality weight loss** that preserves lean mass and function. **Inte…
This economic analysis provides crucial insights for U.S. healthcare payers and clinicians navigating the landscape of emerging **MASH** therapies. **Understanding the cost-effectiveness of resmetirom, semaglutide, an…
This study positions **tirzepatide as a promising therapeutic strategy for preventing vascular remodeling and abdominal aortic aneurysm development**. For individuals at high risk of AAA, particularly those with metab…
This review proposes a significant shift in **surgical prehabilitation**, suggesting that **GLP-1RAs** could become a standard pharmacological component. For clinicians and biohackers, this implies a potential new app…
This pilot trial represents a crucial exploratory step in addressing the significant unmet medical need for effective pharmacological treatments for **Cannabis Use Disorder (CUD)**. If **tirzepatide** demonstrates a p…
This study, once completed, could provide critical data for understanding the full spectrum of GLP-1RA effects beyond just weight loss. **Clinicians and individuals using GLP-1RAs could gain insights into how these me…
**Understanding the role of metabolic adaptation in weight regain is crucial for optimizing long-term obesity management.** If this study demonstrates that **tirzepatide** effectively mitigates adverse metabolic adapt…
This annual review by the PEER team significantly streamlines the process for primary care clinicians to stay current with the latest evidence. **Practitioners can quickly access a vetted summary of high-impact resear…
This comprehensive analysis underscores that **Tirzepatide offers a new benchmark for managing type 2 diabetes and obesity**, potentially leading to superior outcomes compared to previous single-incretin therapies. Fo…
This study highlights the critical need for sustained support and therapeutic options for individuals managing **obesity disease** beyond the duration of a clinical trial. The strong desire of **75.9%** of participant…
This trial could establish a novel therapeutic strategy for **atrial fibrillation** management, particularly in overweight or obese patients undergoing ablation. If successful, **tirzepatide** could become a critical …
Ensuring consistent **tirzepatide** delivery across different devices is crucial for patient safety and efficacy, especially as new administration options emerge. This type of study informs regulatory approvals and de…
This research significantly expands our understanding of **Tirzepatide's** direct cardiac actions, moving beyond its established metabolic benefits. For peptide users and clinicians, this suggests that **Tirzepatide**…
This meta-analysis provides compelling evidence that **tirzepatide** offers comprehensive cardiometabolic benefits beyond just weight loss for non-diabetic adults with obesity. **For individuals managing obesity, this…
This case underscores the critical importance of **pursuing advanced imaging like EUS** when clinical and biochemical evidence strongly suggests an **insulinoma**, even if initial cross-sectional imaging like CT is ne…
This case highlights a critical, previously undocumented adverse event for individuals using **GLP-1RAs** like tirzepatide. **Patients experiencing new or worsening focal abdominal pain while on GLP-1RA therapy should…
This meta-analysis provides compelling evidence that **GLP-1RAs and tirzepatide offer significant cardiovascular benefits in HFpEF/HFmrEF patients, irrespective of their diabetes status**. This finding expands the pot…
Understanding the precise duration required for gastric emptying to normalize after **tirzepatide** discontinuation is critical for patient safety, especially for those undergoing elective surgeries or procedures requ…
**Initiation of this trial marks a significant step towards understanding Tirzepatide's potential beyond glycemic control and weight loss.** If successful, this research could pave the way for a novel therapeutic appr…
Planned study enrolling **200** patients will assess genetic, microbiome, and behavioral impacts on dual GLP-1/GIP RA effectiveness in **obesity**.
If positive, this pilot study could represent a significant step towards repurposing **tirzepatide** as an anti-aging therapeutic, extending its benefits beyond metabolic health. **A positive outcome would suggest tha…
Extrapancreatic effects of GIP and GLP-1, separate and combined, are investigated to elucidate mechanisms of dual incretin agonists like tirzepatide.
This updated Cochrane review underscores a critical gap in our understanding: the long-term impact of weight-reducing drugs on **cardiovascular outcomes and mortality in hypertensive patients is still not definitively…
This meta-analysis reinforces the robust cardiovascular protective profile of **semaglutide** for individuals with **type 2 diabetes mellitus** and **obesity**, particularly regarding `MACE`, cardiovascular mortality,…
This review solidifies **Tirzepatide**'s emerging role as a comprehensive therapeutic option for integrated cardiometabolic risk reduction, extending beyond glucose control and weight loss. For individuals managing **…
This study provides compelling real-world evidence that **Tirzepatide** may offer superior pre-operative optimization for obese patients undergoing spinal fusion compared to single-receptor `GLP-1` agonists. **Clinici…
This guidance represents a paradigm shift for **obesity care in Switzerland**, moving beyond a simplistic focus on weight to a holistic, patient-centered approach. For clinicians, it provides a clear, tiered framework…
If successful, this study could establish **tirzepatide** as a crucial adjunctive treatment for patients with **Mild Autonomous Cortisol Secretion (MACS)** who continue to suffer from metabolic issues post-adrenalecto…
If the SUMMIT trial confirms its hypothesis, **Tirzepatide could emerge as a dual-action therapeutic for HFpEF patients with obesity**, addressing both metabolic and cardiac aspects. This would be a significant advanc…
This large real-world study provides compelling evidence that **tirzepatide offers superior weight loss efficacy and potentially better tolerability compared to semaglutide** in a diverse patient population. For clini…
While specific results are not detailed in the abstract, this study's design to directly compare **semaglutide**, **tirzepatide**, and **sleeve gastrectomy** in a large real-world cohort of **type 2 diabetes** and **o…
This study provides crucial real-world evidence for clinicians managing **IBD** patients with **obesity** and/or **diabetes**. **Adjunctive semaglutide or tirzepatide does not appear to offer additional benefit for IB…
GLP-1-based therapies for obesity converge on multiple biological pathways, reducing systemic inflammation and congestion to improve cardiovascular outcomes in HFpEF.
This first report of **Tirzepatide**-associated **PLEVA** is crucial for expanding the known safety profile of **GLP-1/GIP receptor agonists**. For clinicians prescribing **Tirzepatide**, this adds a rare but signific…
If **HDM1005** demonstrates comparable or superior efficacy and safety to **tirzepatide**, it could offer a valuable new therapeutic option for **obesity** management. This would significantly expand the arsenal of av…
This review solidifies the role of **GLP-1 receptor agonists** as a transformative treatment for **HFpEF**, particularly in patients with obesity. **For clinicians and biohackers, this means GLP-1 RAs are now a frontl…
This analysis provides crucial evidence supporting **tirzepatide's use as a safe and effective option for older adults with obesity**. Previously, limited data left a gap in understanding its utility in this vulnerabl…
This meta-analysis highlights that while highly effective weight loss agents like **tirzepatide** and **liraglutide** significantly reduce fat mass, they also lead to notable lean body mass loss. **Optimizing body com…
A new clinical trial will evaluate tirzepatide's efficacy and safety for managing excess weight in adults with **Type 1 Diabetes** using MiniMed 780G, addressing a critical unmet need.
A 24-week study compares weekly **semaglutide** 2.4mg and **tirzepatide** 10mg against placebo on gastric emptying, accommodation, and satiation.
Free, no account — handy when you're working with Tirzepatide.